EU Revising Supply Chain, Records and Openness Requirements
This article was originally published in The Gold Sheet
Executive Summary
The European Commission’s Directorate-General for Health and Consumer Affairs has launched consultation processes on revisions to its GMP guidelines as part of an effort to strengthen the supply chain of drug products marketed in the European Union.
You may also be interested in...
FDA and EMA Revising GMP Regulations to Address Supply Chain Deficiencies
FDA, EMA revising GMPs to establish supply chain controls. FDA looks to require identification and auditing of ingredient suppliers, heightened component security, notification of significant defects. EMA to require detailed API supply chain pedigrees and more technical agreements. QPs will have to really vouch for API sites. FDA also plans other GMP changes.
Transparency Looms Large In US FDA’s Next-Pandemic Legislative Agenda
Agency’s proposals for pandemic preparedness reauthorization would build on CARES Act provisions to gain greater visibility into global pharmaceutical supply chains, while also seeking deeper understanding of manufacturing quality management activities. Also included in FY 2024 budget request: long-sought drug destruction and drug recall authorities.
US FDA ‘Brainstorms’ For Ways To Resume Pre-Pandemic Inspection Cadence
The FDA's drug inspections director discusses trends and challenges in remarks at a Georgia GMP conference, while declining to share specific ideas generated in last week’s agency brainstorming session.